TScan Therapeutics (TCRX) Short-term Investments (2023 - 2025)

TScan Therapeutics (TCRX) has 3 years of Short-term Investments data on file, last reported at $14.9 million in Q3 2025.

• On a quarterly basis, Short-term Investments fell 89.17% year-over-year to $14.9 million in Q3 2025; TTM through Sep 2025 was $14.9 million, a 89.17% decrease from a year earlier, with the FY2024 full-year figure at $111.4 million, up 89.86% from the prior year.
• Short-term Investments for Q3 2025 stood at $14.9 million, down from $48.7 million in the prior quarter.
• Over the last five years, Short-term Investments for TCRX reached as high as $138.0 million in Q3 2024 and fell as low as $14.9 million in Q3 2025.
• Historically, Short-term Investments has averaged $67.5 million across 3 years, with a median of $58.7 million in 2023.
• On a YoY basis, Short-term Investments climbed as much as 338.17% in 2025 and fell as far as 89.17% in 2025.
• Year by year, Short-term Investments stood at $58.7 million in 2023, then soared by 89.86% to $111.4 million in 2024, then tumbled by 86.59% to $14.9 million in 2025.
• Per Business Quant data, the three most recent Short-term Investments figures were $14.9 million in Q3 2025, $48.7 million in Q2 2025, and $97.6 million in Q1 2025.